Development and Evaluation of a Real-Time Reverse Transcription-Loop-Mediated Isothermal Amplification Assay for Rapid Detection of Rift Valley Fever Virus in Clinical Specimens


Special Pathogens Unit, National Institute for Communicable Diseases of the National Health Laboratory Services, Private Bag X4, Sandringham 2131, Republic of South Africa; Center for International Collaborative Research, Institute for Tropical Medicine, Nagasaki University, 1-12-4, Sakamoto, Nagasaki 852-8523, Japan; Department of Microbiology and Plant Pathology, Faculty of Natural and Agriculture Sciences, University of Pretoria, Pretoria 0002, Republic of South Africa; Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4, Sakamoto, Nagasaki 852-8523, Japan; and Division of Virology and Communicable Disease Surveillance, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa

Received 23 July 2008/Returned for modification 28 August 2008/Accepted 12 December 2008

This paper reports on the development and validation of a real-time reverse transcription-loop-mediated isothermal amplification assay (RT-LAMP) targeting the genomic large RNA segment of Rift Valley fever virus (RVFV). The set of six designed RT-LAMP primers identified strains of RVFV isolated in geographically distinct areas over a period of 50 years; there was no cross-reactivity with other genetically related and unrelated arboviruses. When testing serial sera and plasma from sheep experimentally infected with wild-type RVFV, there was 100% agreement between results of the RT-LAMP, a TaqMan-based real-time PCR, and virus isolation. Similarly, the assay had very high levels of diagnostic sensitivity and specificity when testing various clinical specimens from humans and animals naturally infected with the virus during recent outbreaks of the disease in Africa. The detection of specific viral genome targets in positive clinical specimens was achieved in less than 30 min. As a highly accurate, rapid, and very simple nucleic acid detection format, the RT-LAMP has the potential to be used in less-well-equipped laboratories in Africa and as a portable device during RVF outbreaks in remote areas, and it can be a valuable tool for the differential diagnosis of viral hemorrhagic fevers.

Rift Valley fever (RVF) is an acute disease of domestic ruminants in Africa and Madagascar, caused by a mosquito-borne virus of the genus Phlebovirus of the family Bunyaviridae (18). Since RVF virus (RVFV) was first isolated in 1930 in the Rift Valley in Kenya, it periodically causes large epidemics in domestic ruminants, characterized by high levels of mortality among newborns and abortions in pregnant animals (30). Humans become infected through a mosquito bite, by the handling of aborted fetal material, or during the slaughter of infected animals and typically develop a mild, self-limiting febrile disease (30). However, severe illness, including retinitis, hepatocellular failure, acute renal failure, meningoencephalitis, and hemorrhagic manifestations, occurs in a small proportion of patients (10, 12, 13).

Techniques for the diagnosis of RVF include virus isolation, detection of specific antibody responses, and molecular assays. RVFV can be isolated from serum or whole blood during the febrile stage of the disease as well as from the livers, spleens, and brains of animals who have succumbed to the disease or aborted fetuses. Isolation of the virus is achieved in hamsters, infant or adult mice, and various cell cultures (35). Various serological assays are used to detect antibodies against RVFV, but the virus neutralization test is regarded as the gold standard (23). It is highly accurate, with little or no cross-neutralization with other phleboviruses (33), but since it requires live virus, it can be done only in biocontainment facilities. Enzyme-linked immunosorbent assays, based on inactivated sucrose-acetone-extracted antigens derived from tissue culture or mouse brain, have been extensively validated for the serodiagnosis of RVF (22, 23). However, their production requires biocontainment facilities to limit the risk of exposure of laboratory personnel to infection (9, 29). An indirect enzyme-linked immunosorbent assay based on the recombinant nucleocapsid protein of RVFV has been recently developed for the detection of specific antibodies in human and animal sera (6, 24, 25). Highly sensitive PCR assays for the detection and quantification of RVFV have been reported, including reverse transcriptase PCR (3, 28) and real-time detection PCR (RTD-PCR) based on TaqMan probe technology (2), but they have not been validated for routine diagnostic use.

The loop-mediated isothermal amplification (LAMP) method has been shown to be highly accurate for the detection of DNA (4, 20) and RNA (14, 32, 36) viruses, differentiation of viral serotypes and subtypes (17, 21), and rapid diagnosis of bacterial infections (5). LAMP amplifies target nucleic acid under isother-
TABLE 1. Primers used for RT-LAMP of the polymerase gene (L segment) of RVFV

<table>
<thead>
<tr>
<th>Primer description</th>
<th>Primer name</th>
<th>Genome position (bp)</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forward outer</td>
<td>F3</td>
<td>4081–4100</td>
<td>TGGGGATCTAGG AAGAAGTT GAGGCTAGACTT TACAAACT</td>
</tr>
<tr>
<td>Backward outer</td>
<td>B3</td>
<td>4269–4289</td>
<td>21</td>
</tr>
<tr>
<td>Forward inner</td>
<td>F1c</td>
<td>4149–4172</td>
<td>44</td>
</tr>
<tr>
<td>Backward inner</td>
<td>B1c</td>
<td>4186–4207</td>
<td>41</td>
</tr>
<tr>
<td>Loop forward</td>
<td>LF</td>
<td>4123–4147</td>
<td>25</td>
</tr>
<tr>
<td>Loop backward</td>
<td>LB</td>
<td>4212–4234</td>
<td>23</td>
</tr>
</tbody>
</table>

TABLE 2. Identification, year of isolation, source, and origin of RVFV isolates

<table>
<thead>
<tr>
<th>Identification</th>
<th>Yr of isolation</th>
<th>Source</th>
<th>Origin</th>
<th>Genetic lineage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Log&lt;sub&gt;10&lt;/sub&gt; TCID&lt;sub&gt;50&lt;/sub&gt; titer/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNS UGA44</td>
<td>1944</td>
<td>Smithburn strain</td>
<td>Uganda</td>
<td>C</td>
<td>10&lt;sup&gt;3.2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lunyo UGA55</td>
<td>1955</td>
<td>Mosquito</td>
<td>Uganda</td>
<td>C</td>
<td>10&lt;sup&gt;3.8&lt;/sup&gt;</td>
</tr>
<tr>
<td>ArB1976CAR69</td>
<td>1969</td>
<td>Mosquito</td>
<td>Central African Republic</td>
<td>C</td>
<td>10&lt;sup&gt;3.8&lt;/sup&gt;</td>
</tr>
<tr>
<td>VRL2373ZI</td>
<td>1974</td>
<td>Bovine</td>
<td>Zimbabwe</td>
<td>C</td>
<td>10&lt;sup&gt;3.3&lt;/sup&gt;</td>
</tr>
<tr>
<td>H1825RSA75</td>
<td>1975</td>
<td>Human</td>
<td>South Africa</td>
<td>C</td>
<td>10&lt;sup&gt;7.0&lt;/sup&gt;</td>
</tr>
<tr>
<td>B1143KEN77</td>
<td>1977</td>
<td>Human</td>
<td>Kenya</td>
<td>C</td>
<td>10&lt;sup&gt;3.8&lt;/sup&gt;</td>
</tr>
<tr>
<td>ZHS01EGY77&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1977</td>
<td>Human</td>
<td>Egypt</td>
<td>E</td>
<td>10&lt;sup&gt;3.8&lt;/sup&gt;</td>
</tr>
<tr>
<td>ZHS548EGY77</td>
<td>1977</td>
<td>Human</td>
<td>Egypt</td>
<td>E</td>
<td>10&lt;sup&gt;3.3&lt;/sup&gt;</td>
</tr>
<tr>
<td>VRL1187ZIM78</td>
<td>1978</td>
<td>Bovine</td>
<td>Zimbabwe</td>
<td>C</td>
<td>10&lt;sup&gt;3.0&lt;/sup&gt;</td>
</tr>
<tr>
<td>ArS111MAD79</td>
<td>1979</td>
<td>Mosquito</td>
<td>Madagascar</td>
<td>E</td>
<td>10&lt;sup&gt;3.3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ar2036RSA81&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1981</td>
<td>Mosquito</td>
<td>South Africa</td>
<td>C</td>
<td>10&lt;sup&gt;3.8&lt;/sup&gt;</td>
</tr>
<tr>
<td>ArD3838BF83</td>
<td>1983</td>
<td>Mosquito</td>
<td>Burkina Faso</td>
<td>W</td>
<td>10&lt;sup&gt;3.8&lt;/sup&gt;</td>
</tr>
<tr>
<td>ArD38661SEN83&lt;sup&gt;d&lt;/sup&gt;</td>
<td>1983</td>
<td>Mosquito</td>
<td>Senegal</td>
<td>W</td>
<td>10&lt;sup&gt;1.3&lt;/sup&gt;</td>
</tr>
<tr>
<td>R1662CAR85&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1985</td>
<td>Human</td>
<td>Central African Republic</td>
<td>C</td>
<td>10&lt;sup&gt;3.5&lt;/sup&gt;</td>
</tr>
<tr>
<td>SPU384001KEN97</td>
<td>1997</td>
<td>Human</td>
<td>Kenya</td>
<td>C</td>
<td>10&lt;sup&gt;3.3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ar2199SA00</td>
<td>2000</td>
<td>Mosquito</td>
<td>Saudi Arabia</td>
<td>C</td>
<td>10&lt;sup&gt;3.0&lt;/sup&gt;</td>
</tr>
<tr>
<td>SPU22.118KEN07&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2007</td>
<td>Human</td>
<td>Kenya</td>
<td>C</td>
<td>10&lt;sup&gt;3.8&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> C, southern, eastern, and central African lineage; E, Egyptian lineage; W, West African lineage.
<sup>b</sup> Strain selected for determination of analytical detection limit.
Communicable Diseases, Sandringham, South Africa. All the viruses were amplified either in Vero cells (CCL-81) or in sucking mice by using standard procedures (31).

Clinical specimens. Serial bleed samples (n = 20) taken from two sheep from day 0 to day 12 after experimental infection with the SPU22/07 Kenyan 2007 isolate of RVFV were tested; these samples included serum derived from clotted blood and plasma (n = 6) collected in EDTA as well as heparin blood collection tubes. In addition, routine diagnostic submissions received by the Special Pathogens Unit of the National Institute for Communicable Diseases in 2006 to 2008 from suspected cases of RVF in humans (n = 65) and animals (n = 3) in eastern and southern Africa were used; these included serum, liver, and kidney tissue specimens, as specified in Table 4.

Virus titration and isolation. Virus titration of infected tissue culture supernatants and sera from experimentally infected sheep was performed as described previously (31) with minor modifications. Briefly, sera were diluted tenfold in Eagle's minimum essential medium (MEM; BioWhittaker) containing 100 IU penicillin, 100 µg streptomycin, and 0.25 µg amphotericin B (BioWhittaker). Four replicates of 100 µl each per dilution (from 10-1 to 10-4) were transferred into flat-bottom 96-well cell culture microplates (Nunc), and equal volumes of Vero cell suspension in MEMEM containing 2 × 105 cells/ml, 8% fetal bovine serum/ml (Gibco), and antibiotics were added. Inoculated microplates were incubated at 37°C in a CO2 incubator and observed microscopically for cytopathic effects for 10 days postinculation. Virus titers, calculated by the Kärber method (8), were expressed as TCID50 per milliliter of sample. The limit of detection was 0.75 log10 TCID50 per volume of sample tested. Isolations of RVFV from clinical specimens were done by inoculation of either 48-h monolayers of Vero cells or sucking mice by using standard laboratory procedures (35).

RNA extraction. Animal tissues were homogenized as 10% (w/v) suspensions in MEMEM supplemented with antibiotics as described above. After centrifugation at 10,000 g, supernatants free of cells were harvested and stored at −70°C. Genomic viral RNA was extracted from 140 µl of infected Vero cells tissue culture supernatants, liver and kidney tissue supernatants, or sera by using a QIAamp viral RNA mini kit (Qiagen, Germany) in accordance with the manufacturer's protocol. The extracted RNA was eluted in a total volume of 60 µl of buffer AVE and stored at −70°C until use.

TaqMan RTD-PCR. The TaqMan RTD-PCR assay was performed using a LightCycler RNA amplification kit Hy_pull (Roche Diagnostics, Germany) and a Roche LightCycler instrument. Amplifications were carried out in 20 µl reaction mixtures containing 5 µl of the target virus RNA or the in vitro transcribed RNA standard, 1 µM concentrations of each of the sense and antisense primers, and 5 mM MgCl2. Cycling profiles, primers, and a TaqMan probe targeting a region of the G2 glycoprotein as described by Drosten et al. (2) were used.

RT-LAMP. RT-LAMP was carried out in a final reaction volume of 25 µl using a LightCycler RNA amplification kit (Eiken Chemical Co., Ltd, Tokyo, Japan) with 5 pmol (each) of the primers F3 and B3, 20 pmol (each) of the primers LF and LB, and 40 pmol (each) of the primers FIP and BIP. Five microliters of the extracted RNA was used as template per reaction. For real-time monitoring, the RT-LAMP reactions were incubated at 61°C for 60 min with a LA-200 Loopamp Realtime Thermobidimeter (Terafast, Japan) and inactivated at 80°C for 5 min. Positive and negative controls were included in each run of the assay.

Analysis of RT-LAMP product. (i) Real-time monitoring. A real-time turbidimeter was used to spectrophotometrically monitor every 6 s the accumulation of magnesium pyrophosphate in the bottom of the tubes to detect amplification with the naked eye. Alternatively, 1 µl of fluorescent detection reagent (FDR; Eiken Chemical Co., Ltd, Tokyo, Japan) was added to the LAMP reaction. The FDR contains calcein complexed with manganese ions. Fluorescence occurs when pyrophosphate ions (formed as a by-product during LAMP amplification) removes the manganese ions from the calcein and binds to the calcein in the FDR. Fluorescence is further intensified when the calcein binds to magnesium ions in the reaction (16). For a positive reaction, orange changes to yellow fluorescence that can be detected with the naked eye or to green fluorescence under UV irradiation, while a negative reaction remains the orange color of the unbound dye. The color change can be observed by the naked eye or with the aid of UV light at 302 nm, and the results are captured photographically.

(iv) Restriction endonuclease digestion. Amplification products were digested with BstXI (Roche, Germany) as suggested by the manufacturer and analyzed with a 2% agarose gel as described above.

In vitro transcription and quantification. To obtain a quantitative RNA standard, the diagnostic target region was amplified by standard reverse transcriptase PCR using RVFV RNA prepared from infected tissue culture supernatant and transcribed in vitro. The primers for the RVF RTD-PCR or RVF-LAMP outer primers were used, respectively, to generate amplicons representative of the RTD-PCR or LAMP targets. The target region PCR products were cloned into pT7Sp6 polymerase expression vector pCRII-TOPO (Invitrogen). The inserts were then amplified with vector-specific, universal M13 primers using standard PCR. The PCR products were purified using a Wizard SV Gel and PCR Clean Up system (Promega) and then in vitro transcribed and DNase digested using a MegaScript Sp6 kit (Ambion) according to the manufacturer’s protocol. The RNA was purified according to the instructions of the RNaseasy Protect kit (Qiagen, Germany) and quantified spectrophotometrically. The target RNA copy number was calculated, and serial dilutions ranging from 106 to 102 RNA copies were used to determine the range of quantification.

Analytical sensitivities of TaqMan RTD-PCR and RT-LAMP. To compare the analytical sensitivities of RT-LAMP and TaqMan RTD-PCR in the detection of decreasing number of RNA copies, tenfold dilution series of the RNA standard, ranging from 106 to 102 per reaction, were tested in six separate runs of each assay.

RESULTS

Optimum specific amplification was achieved at 61°C for 60 min. This was determined during the optimization of the RVF RT-LAMP when 10 pg of RNA (extracted from SPU 22/07) was incubated at a range of 61 to 65°C and could be detected only at 61°C. No nonspecific amplification was detected for the negative serum and tissue culture controls. A Tp value (time of positivity, i.e., time [in minutes] at which the turbidity increases above the threshold value fixed at 0.1) of ≥45 min and turbidity above the threshold value of ≥0.1 were considered a positive result (19). Real-time monitoring of turbidity allowed for the detection of amplification products as early as 16 min after initiation of the reaction, with the majority of positive specimens detected in less than 30 min.

Analytical sensitivity and specificity of RT-LAMP. When the sensitivity of the RT-LAMP was compared with that of a TaqMan RTD-PCR by testing tenfold serial dilutions of RNA prepared from infective tissue culture supernatant containing 106.8 TCID50/ml of the AR20368 RSA 81 isolate of RVFV, the two assays were equally sensitive, with a detection limit of 0.065 TCID50 units per reaction volume (Fig. 1 A and B). The RT-LAMP detection limit of 0.065 TCID50 units per reaction volume was further confirmed by testing tenfold serial dilutions of four additional strains of RVFV (Table 2), representing a phylogenetic spectrum of the virus (results not shown).

High levels of analytical sensitivity for both assays were also demonstrated by measuring decreasing numbers of RNA copies. The RNA standard dose-response curves for TaqMan RTD-PCR and RT-LAMP were very similar to one another (R2 of 0.8386 and 0.8042, respectively) and had the expected characteristic slope (Fig. 2). The borderline analytical detection limit as measured by number of RNA copies per reaction was 10 copies for both assays. During six runs, TaqMan RTD-PCR detected 10 RNA copies/reaction on four occasions (66.7%) and the RT-LAMP on three occasions (50%). However, this difference was not statistically significant (P = 1.0000). Both assays had 100% sensitivity in detecting ≥100
RNA copies/reaction (Fig. 2). Despite distinct geographic and historic origins, all the RVFV isolates tested in this study were easily detectable by the RT-LAMP (Table 2), further confirming its high level of analytical sensitivity. The high level of analytical specificity of the assay was confirmed by the absence of amplification products when using the RVFV-specific L primer set with RNA extracted from highly concentrated stocks of six African phleboviruses related to RVFV and six other, unrelated arboviruses (results not shown). In addition, the specificity of the RT-LAMP amplification product was confirmed by restriction endonuclease digestion with BstXI, resulting in a product with the expected size of 209 bp (result not shown).

Alternative detection methods included agarose gel electrophoresis of the RT-LAMP products, which displayed the typical ladder-like pattern (Fig. 3), as well as FDR detection of amplification (Fig. 4). The fluorescent dye became yellow in positive samples (Fig. 4A) and showed deep green fluorescence with UV irradiation (Fig. 4B).

Diagnostic evaluation of RT-LAMP. Results of monitoring viremia by RT-LAMP, TaqMan RTD-PCR, and virus titration in two sheep experimentally infected with the wild-type isolate of RVFV are shown in Table 3. All three assays yielded negative results in sera collected before challenge. Of the sera collected on a daily basis postinfection, 11 tested positive and 9 tested negative in all tests (Table 3). The two molecular assays yielded the same results in experimental sheep plasma collected either in EDTA or heparin, but there was a slight delay in the detection of RNA extracted from heparin treated blood by the RT-LAMP.

Of the total of 32 human serum specimens which tested positive by virus isolation, all but one were also positive by the RT-LAMP and TaqMan RTD-PCR. One human serum sample which tested negative by virus isolation yielded positive results in the two molecular assays (Table 4). There was 100% agreement between the RT-LAMP, TaqMan RTD-PCR, and virus isolation results in detecting RVFV in liver and kidney tissues collected from three aborted buffalo fetuses (Table 4).
DISCUSSION

RVF is an important zoonotic disease and poses a potential bioterrorism threat (11, 26). The recent occurrence of the first confirmed outbreaks of RVF among humans and animals outside Africa (7), the ability of RVFV to replicate in a wide range of mosquito vectors (34), and the effects of global climate change which facilitate spread of arthropod-borne viruses (27) into regions of the world in which the virus is not endemic are of great medical and veterinary concern. The potential for further spread of RVFV outside its traditional geographic boundaries has resulted in increased international demand for validated molecular tools for the rapid diagnosis of RVF. RVFV belongs to the group of RNA viral hemorrhagic fever (VHF) agents, including Ebola virus, Marburg virus, Lassa and...
other arenaviruses, Crimean-Congo hemorrhagic fever virus, yellow fever virus, dengue virus, and hantaviruses. In the absence of hemorrhagic or specific organ manifestations, infections by VHF viruses are clinically difficult to recognize, with the implication that definitive diagnosis depends mainly on reliable laboratory tests (2). Although the range of possible VHF agents can be narrowed down by the patient’s travel and exposure history, a suspected case and the causative virus must be rapidly identified to initiate specific or supportive treatment and to implement appropriate case management, infection control, and tracing of contacts.

An array of molecular techniques for rapid detection and identification of RVFV have been published, but data on their routine diagnostic performance are not available (2, 3). In this study, the utility of the LAMP technique for rapid and accurate detection of RVFV RNA in clinical specimens was investigated. Including the time required for the extraction of nucleic acid, detection of RNA in different clinical specimens of human and animal origin could be achieved within 2 h after arrival of the samples in the laboratory. Apart from the high levels of analytical and diagnostic accuracy and speed of detection, another important practical advantage of the LAMP technique is that it utilizes simple and relatively inexpensive equipment, which renders it promising for use in resource-poor settings. In addition, only basic molecular and technical skills are required for execution of the assay procedure, and interpretation of the results may be as simple as a visual evaluation of color change in the reaction mix. However, primer design for LAMP is more complex than for the conventional PCR-based assays, and specialized training and software are required for their design. Moreover, the development of LAMP requires the use of a set of multiple primers spanning a highly conserved 300-bp genomic region. For RVFV, this is easily achievable because there is no evidence of serological subgroups or major antigenic variation between isolates of disparate chronologic or geographic origins (30), which is due to their low level of genetic diversity, irrespective of the genome segments analyzed (1). In the present work, we demonstrate that the set of LAMP primers targeting the RNA-dependent RNA-polymerase gene of the L segment of RVFV is well designed to detect all strains of the virus.

Results of the study show that the sensitivities of the RT-LAMP and TaqMan RTD-PCR assays are similar and that there is no cross-reactivity of the primers with the genes of related and unrelated arboviruses. Both assays had high levels of analytical sensitivity as measured by the detection of a known number of virus infectious doses and RNA copies of the in vitro-transcribed RNA standard. Similar analytical sensitivity for the TaqMan RTD-PCR based on the Superscript reverse transcriptase-Platinum Taq polymerase enzyme mixture was reported by Drosten et al. (2). By direct comparison of the two nucleic acid procedures with virus isolation results for clinical specimens from animals and humans, the diagnostic performance of the TaqMan RTD-PCR assay for the detection of RVFV is also reported here for the first time. Specific nucleic acid targets in all positive specimens could be detected in the study in less than 45 min, with the majority detected in less than 30 min. This result confirms that the assay allows for rapid confirmation of clinical cases and early recognition of outbreaks. Visualization of amplification products with the naked eye, fluorescence, or agarose gel electrophoresis may be appropriate for most laboratory settings, while real-time monitoring of the accumulation of magnesium pyrophosphate in the reaction mix potentiates quantification of the assay. One has to emphasize, however, that definitive diagnosis or exclusion of RVF, as for any other suspected case of VHF, should not rely on a single PCR result. The LAMP should be run in parallel with additional tests, including the detection of type-specific antibodies to RVFV. In this con-
text, it is important to note that viremia in RVFV-infected individuals is of very short duration (30) and most infected humans and adult ruminants undergo subclinical or mild infections, but immunoglobulin M and immunoglobulin G antibodies are easily demonstrable shortly after exposure to the virus (22, 23).

ACKNOWLEDGMENTS

We are grateful for financial support of the study by the Polio Research Foundation (grant number 06/07), the 21st Century COE Program, and the Program of founding Research Centers for Emerging and Reemerging Infectious Diseases, Mext, Japan. C. Le Roux was sponsored by a National Health Laboratory Service scholarship for postgraduate studies.

We thank the following employees of the National Health Laboratory Service, South Africa: Pat Leman for technical laboratory assistance and Guy Hall for photographic assistance.

ADDITION IN PROOF

We notice and acknowledge that an article describing a similar technique for the detection of Rift Valley fever virus (C. N. Peyrefitte, L. Boulib, D. Court, M. Bouloy, M. Grandadam, H. J. Toleu, and S. Plumet, J. Clin. Microbiol. 46:3653–3659, 2008) was recently published in the Journal of Clinical Microbiology.

REFERENCES